PISCATAWAY, N.J., Aug. 8, 2011/PRNewswire/ --INNOPHARMA LLC announced today FDA approval of its Abbreviated New Drug Application (ANDA) for levetiracetam injection (the generic equivalent of Keppra® injection from UCB Inc).
As the developer of this generic injectable drug, INNOPHARMA entered into a license agreement with X-GEN Pharmaceuticals, Inc. for marketing and product distribution in the US.
About INNOPHARMA:
INNOPHARMA is a sterile product development company, focused on developing niche generic and specialty pharmaceutical products. Through a business model of internal product development and commercialization licensure, INNOPHARMA has a comprehensive infrastructure for development of injectable and ophthalmic pharmaceutical products at its New Jersey facilities. INNOPHARMA works with manufacturing and clinical research organizations worldwide for commercialization of its developed products. More information about INNOPHARMA can be found at www.innopharmallc.com.
About X-GEN:
X-GEN Pharmaceuticals, Inc. is focused on the development, manufacture and delivery of specialty pharmaceutical products which serve the healthcare community as effective, generic treatment choices. X-GEN’s expanding product line offers a broad range of dosage forms including injectables, anti-infective solutions, oral solids, and inhalants. For more information about X-GEN Pharmaceuticals, Inc. call (866) 390-4411, or visit the web-site at www.x-gen.us.
SOURCE INNOPHARMA LLC
